Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4669 Efficacy and safety of [177Lu]Lu-edotreotide vs. everolimus in patients with grade 1 or grade 2 gastroenteropancreatic neuroendocrine tumours: COMPETE phase 3 trial

Introduction: Patients with metastatic gastroenteropancreatic neuroendocrine tumours (GEP-NET) have limited therapeutic options.

Conference:

Presenting Author:

Authors: Capdevila J, Amthauer H, Ansquer C, Deshayes E, Garcia-Carbonero R,

Keywords: radiopharmaceutical therapy, neuroendocrine tumour, [177Lu]Lu-edotreotide, progression-free survival, gastroenteropancreatic,

#4590 Association of SST5TMD4 and SST5TMD5 expression with metastasis and poor prognostic markers in gastroenteropancreatic neuroendocrine tumours

Introduction: The expression of the somatostatin receptor isoform SST5TMD4 is linked to poorer prognosis in somatotropinomas, as well as in breast and thyroid cancers, and it is notably overexpressed in gastroenteropancreatic neuroendocrine tumours (GEP-NETs).

Conference:

Presenting Author: Pedraza-Arevalo S

Authors: Pedraza-Arévalo S, Díaz-Pérez J, Garcia-Carbonero R, Villabona C, Capdevila J,

Keywords: GEP-NET, somatostatin, truncated receptor, metastasis,

#4069 Impact of nutritional status in the quality of life (QoL) of patients with advanced gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) in Spain: NUTRIGETNE Study

Introduction: Prevalence of malnutrition and sarcopenia is high among patients with advanced GEP-NENs and may significantly decrease response to therapy and impair QoL.

Conference:

Presenting Author:

Authors: Del Olmo-García M, Garcia-Carbonero R, Hernando J, Pérez-Wert P, Suarez Gutiérrez L,

Keywords: nutritional status, Gastroenteropancreatic, Neuroendocrine neoplasm, Sarcopenia, Malnutrition,

#4015 Responses to Cabozantinib plus Atezolizumab in a wide population of advanced and progressive neuroendocrine neoplasms (NENs): A prospective multi-cohort basket phase II Trial (CABATEN / GETNE-T1914)

Introduction: Angiogenesis plays a key role in development and progression of NENs and synergism has been observed when combined with immune-checkpoint inhibitors in other tumors.

Conference:

Presenting Author: Molina-Cerrillo J

Authors: Molina-Cerrillo J, Grande E, Benavent M, Garcia-Carbonero R, Teule A,

Keywords: neuroendocrine neoplasm, Cabozantinib, Atezolizumab, CABATEN, prospective multi-cohort Basket Phase II Trial,

#4013 A phase 3 randomised study of 177Lu-edotreotide or everolimus in patients with advanced neuroendocrine tumors of lung or thymic origin (LEVEL, GETNE-T2217)

Introduction: Retrospective data for peptide receptor radionuclide therapy (PRRT) have demonstrated promising activity in somatostatin receptor (SSTR)-positive lung neuroendocrine tumors (NETs).

Conference:

Presenting Author:

Authors: García-Álvarez A, Garcia-Carbonero R, Anido U, Jimenez-Fonseca P, Del Olmo-García M,

Keywords: Lung NET, Peptide receptor radionuclide therapy,